- $8.72bn
- $8.22bn
- $108.78m
ImmunoGen Inc reports results for the quarter ended in September - Earnings Summary
Brief: ImmunoGen Q3 EPS USD 0.1
ImmunoGen Inc expected to post earnings of 4 cents a share - Earnings Preview
Sutro Biopharma gains as Oppenheimer initiates coverage with 'outperform'
Brief: ImmunoGen Says Elahere Shows Overall And Progression-Free Survival Benefit In FRα-Positive Platinum-Resistant Ovarian Cancer
Brief: Immunogen Appoints Lauren White As Senior Vice President And Chief Financial Officer
U.S. STOCKS ON THE MOVE-Danaher, Goldman Sachs, Generac Holdings
U.S. STOCKS ON THE MOVE-Hawaiian Electric, Novocure, Boston Scientific
ImmunoGen rises on agreement with Takeda for ovarian cancer drug in Japan
Brief: ImmunoGen Announces Collaboration With Takeda To Develop And Commercialize Elahere In Japan
U.S. STOCKS ON THE MOVE-Baxter International, Johnson & Johnson, Ford Motor
U.S. STOCKS ON THE MOVE-Hasbro, Sweetgreen, Innoviz Technologies
ImmunoGen Inc reports results for the quarter ended in June - Earnings Summary
U.S. STOCKS ON THE MOVE-SoFi Technologies, Symbotic, Carnival
U.S. STOCKS ON THE MOVE-ImmunoGen, Adobe, Nikola
Brief: Immunogen Announces Departure Of Anna Berkenblit, Chief Medical Officer
ImmunoGen rallies on Q2 results beat
ImmunoGen Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: ImmunoGen Announces Multi-Target License And Option Agreement With ImmunoBiochem To Develop Next-Generation Antibody-Drug Conjugates